An interventional study of virtual self-management intervention in Breast Cancer Survivor and Colorectal Cancer Survivors, sponsored by Nova Scotia Health Authority. Recruiting at 2 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-14.
Sponsored by Nova Scotia Health Authority · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 907 studies in Breast Neoplasms with a site in Canada — 139 open to participants now, 257 under way, 81 of them phase 3. Breast Neoplasms · Canada.
Among the 907 studies in Breast Neoplasms with a site in Canada, this one is the 557th largest by planned enrollment of the 787 interventional ones that give a count, is one of 24 that started in 2026, is one of 204 with no phase, reaches primary completion later than 113 of the 256 other live ones, and was the 894th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →139 of the 907 studies in Breast Neoplasms with a site in Canada are open now. Recruiting first, the newest first:
Hoffmann-La Roche · Sites in Canada, United States
Ages 18+
University Health Network, Toronto · Sites in Canada
Ages 18+
Novartis Pharmaceuticals · Sites in Canada, United States, Australia and 1 more country
Ages 18+
British Columbia Cancer Agency · Sites in Canada
Ages 40+ · Women only
Novartis Pharmaceuticals · Sites in Canada, United States, France and 6 more countries
Ages 18+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
907 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 129 · Phase 2 246 · Phase 3 255 · Phase 4 25
First in 1988; this study’s year is marked. 24 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Median enrollment 155 across the 787 interventional studies, 199 across the 110 observational. Of the 575 that completed or were terminated, 230 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
374 of 907 have an industry lead sponsor. The 10 most frequent:
Nova Scotia Health Authority is the lead sponsor of 264 studies on the registry; 77 are open to participants now.
Nova Scotia Health Authority has 6 studies filed under Breast Neoplasms — fewer than ten, so there is no comparison to draw.
61 of the studies in Breast Neoplasms with a site in Canada that are under way reach primary completion within a year, 14 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05038735Phase 3Novartis PharmaceuticalsStudy to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor. | 2027-01-28 |
| NCT04906395Phase 3Tolmar Inc.Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer | 2027-01-30 |
| NCT05696626Phase 3LeonaBioEvaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation | 2027-04 |
| NCT04421963Phase 3AstraZenecaRoll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib | 2027-04-06 |
| NCT05774951Phase 3AstraZenecaA Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy | 2027-04-20 |
Add all 61 to your calendar (.ics) → With an account.
Among the 907 studies in Breast Neoplasms with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this study is to determine the feasibility of implementing a mobile health application for breast and colorectal cancer survivors following primary treatment. Developed in collaboration with Seamless MD, the intervention acts as an information hub, providing users with timely and evidence-based information related to follow-up care as well as health system/community-based resources and programs to meet their needs during this period of care. The goal of the intervention is to encourage open communication regarding survivorship expectations and provide survivors with appropriate information and support to meet their needs.
This study will:
Participants will have access to the intervention for a period of six months. Questionnaires will be distributed to participants through the intervention at baseline, 90 days, and 180 days to assess user experience. Semi-structured interviews will be conducted with select survivor participants and healthcare providers (oncology and primary care) to determine the feasibility and acceptability of this intervention.
Inclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Behavioral: virtual self-management intervention
The intervention is a supportive information and self-management tool housed on the SeamlessMD mobile app, created in collaboration with the SeamlessMD development program and informed by foundational research. The application will be used as an information hub and self-management/navigation tool alongside usual care, to address the physical, psychosocial, and practical needs of breast and colorectal cancer survivors. Note that the intervention will not seek to change or impact a survivor's follow-up care plan, as decided upon by the participant and their care team.
Recruitment
Case report forms will be used to track recruitment metrics. The following demographics will be collected to monitor the diversity of those participating: cancer type (breast, colorectal), stage at diagnosis (in situ, stage 1, stage 2, stage 3, do not know), age (in years, prefer not to say), sex assigned at birth (male, female, intersex, prefer not to say), gender (man, woman, non-binary, other, prefer not to say), residence (rural, suburban, urban, prefer not to say), and highest level of education achieved (less than high school, high school, some post-secondary (college or university), diploma or degree, prefer not to say).
Time frame: During enrollment
Retention
Case report forms will be used to track retention metrics.
Time frame: Enrollment to day 180
Usage of the Intervention
Usage metrics will be collected using the SeamlessMD software to determine the following: 1) how often the intervention was accessed by participants, 2) what elements of the intervention were accessed most, and 3) what elements of the program were utilized the least.
Time frame: Baseline to day 180
Survivor and Provider Acceptability and Experience
Assessed via one-on-one semi-structured interviews with a sub-sample of study participants and providers at both study sites. Semi-structured interviews were chosen over focus groups for this component because the research team is seeking individual experiences with the intervention. Interviews will be carried out by a member of the research team on video conferencing software using a predetermined interview guide and will take approximately 45 minutes. The questions will center around the study participant's follow-up care experience while being supported by the intervention. Interviews with providers will focus on the feasibility and acceptability of the supportive self-management tool.
Time frame: Interviews with survivor participants will be conducted after having access to the intervention for 180 days.
Fear of Recurrence
Will be assessed using the 6-item Cancer Worry Scale, a validated patient-reported instrument. Cancer Worry Scale (CWS) scores range from 6 to 24 points. A score of 6 points indicates low worry, while a score of 24 points indicates very high worry.
Time frame: Outcomes will be captured at baseline (study entry), on days 90 and 180, directly through the Seamless MD app software.
Patient Activation
Will be assessed with the 13-item Patient Activation Measure (PAM), a validated patient-reported instrument. PAM includes 13 questions that produce a score on a 0-100 scale, which correlates with 1 of 4 activation levels. A level 1 score indicates low activation, while a level 4 score indicates a high activation.
Time frame: Outcomes will be captured at baseline (study entry), on days 90 and 180, directly through the Seamless MD app software.
Information Provision
There are no validated instruments to assess information provision on its own. Therefore, these will be assessed using modified survey items from the Canadian Transitions Survey, a national survey on survivors' needs and experiences after completing cancer treatment.
Time frame: Outcomes will be captured at baseline (study entry), on days 90 and 180, directly through the Seamless MD app software.
Plan to share: No
No publications or documents are linked to this record.
Started Apr 2026 (actual). Primary completion is estimated for Dec 2026, 8 months after the start.
Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 8 months is below that.
Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Nova Scotia Health Authority →